BaltCap exits Quattromed laboratories to synlab

BaltCap, the Baltic-focused private equity firm, has delivered its latest successful exit, selling Medicap Holding AS to synlab, the leading European provider of laboratory services.

 

synlab has acquired 100% of Medicap Holding, which owns Estonian, Finnish and Lithuanian laboratories operating under the Quattromed and Sorpo brand names, from BaltCap and individual shareholders.

 

By acquiring operations in three new markets, synlab further expands its footprint in Europe and becomes the first international laboratory chain to enter the Baltic markets. Dr. Bartl Wimmer, CEO of synlab, commented: “We are very pleased to add Quattromed and Sorpo labs to the synlab group. The acquisition will strengthen our position as the leading laboratory network in Europe. We have followed the development of these companies for several years and have been impressed by the achievements of the company and its management team.”

 

BaltCap’s managing partner Peeter Saks commented: “We carried out our original investment hypothesis and executed a regional buy and build strategy, growing the company’s revenues by more than four times since 2008. We are pleased that Medicap has now been acquired by an international lab chain with a vision to continue developing and growing the business.”

 

Rainar Aamisepp, CEO of Medicap, was pleased with the development: “The transaction is a compliment to what Medicap companies have achieved so far. I am convinced that together with synlab we will be able to develop our customer-focused services and market penetration further in both Finland and the Baltic States.”

 

Medicap Holding, consisting of Quattromed HTI in Estonia, Sorpo in Lithuania and Quattromed Finland, has a strong position among private medical laboratories in these markets. The group has more than 200 employees and provides more than 5 million laboratory tests per year to general practitioners, medical institutions and private individuals.

 

The buyer’s advisers were law firms CMS Hasche Sigle and Borenius, and audit firm Ernst & Young. The sellers were advised by law firm Red, Attorney at Law.

 

About Synlab

With headquarters in Augsburg, Germany, the synlab group is the leading provider of medical laboratory services in Europe. The company offers a full range of laboratory analysis for human and veterinary medicine as well as the environment. In addition to Germany, it has now, after the latest acquisitions, branches in 21 European countries as well as Turkey, Saudi Arabia and Dubai. The synlab group has around 7,000 employees across Europe including 4,500 in Germany. The synlab network comprises a total of some 175 laboratories and introduces about 60 news tests every year. In 2012, the group generated revenues of EUR 625 million.

www.synlab.com

 

 

For further information, synlab:

Andreas Borchert                                                                          

Head of Marketing & Communications                                            

synlab group                                                                                 

tel.: +49 (0)821 52157-564                                                             

mobile: +49 (0)151 62915870                                                         
e-email: andreas.borchert@synlab.com                                                

 

Ralf Geissler

Director

Perfect Game Communications GmbH

tel.: +49 (0)89 3090529520

mobile: +49 (0)170 9043050

e-mail: rg@perfect-game.de

 

For further information, BaltCap:

Peeter Saks                                                                                   

Managing Partner                                                                         

tel.: +372 665 02 85                                                                      

e-mail: peeter.saks@baltcap.com                                                    

 

Oliver Kullman

Investment Director

tel.:+372 665 02 83

e-mail: oliver.kullman@baltcap.com

 

For further information, Quattromed/Medicap:

Rainar Aamisepp                                                                          

Chief Executive Officer                                                                          

tel.: +372 640 82 10

e-mail: rainar.aamisepp@quattromed.ee
www.quattromed.ee